Therapeutics – WARF

Phenylketonuria: Insights into Pathophysiology and Novel Therapeutics

Chris Najdowski — Fri, 28 Apr 2023 16:30:00 +0000

Phenylketonuria (PKU), due to recessively inherited phenylalanine hydroxylase (PAH) deficiency, is among the most common inborn errors of metabolism with an incidence of 1:16,000 live births in the US. PAH deficiency causes accumulation of the amino acid phenylalanine (Phe) to extremely high concentrations throughout the body but most importantly in brain. The precise molecular mechanisms...

Source

WARF Therapeutics Symposium

Chris Najdowski — Wed, 19 Apr 2023 20:30:00 +0000

Join WARF Therapeutics, the UW-Madison Department of Chemistry and the UW-Madison Synthesis and Catalysis Center for the 2023 WARF Therapeutics Symposium. 3:30-4:15 p.m. Student Presentations Ben Chi, Weix Group Environmentally Friendly Nickel-Catalyzed Reductive Difluoromethylation of Aryl Bromides Emily Schroeder, Schomaker Group Expanding the Scope of Silver-BOX Catalyzed Enantioselective C-H...

Source

Hongmin Chen joins WARF Therapeutics

Chris Najdowski — Mon, 20 Sep 2021 12:55:20 +0000

Chen to head biology for program aiming to produce preclinical candidates CONTACT: Jeanan Yasiri Moe Director of Strategic Communications jyasirimoe@warf.org | (608) 960-9892 MADISON, Wis. – WARF Therapeutics, the multimillion-dollar initiative to advance UW-born biological discoveries into active pharmaceutical ingredients (API) and on to market, has a new Head of Biology. Hongmin Chen...

Source

WARF Therapeutics fall 2021 call for proposals

Chris Najdowski — Tue, 07 Sep 2021 14:45:31 +0000

Program proposal deadline October 8 CONTACT: Jeanan Yasiri Moe Director of Strategic Communications jyasirimoe@warf.org | (608) 960-9892 MADISON, Wis. – WARF Therapeutics collaborates with researchers to advance their work closer to clinical testing, a “bench to bedside” approach. The program invests in the development of drug-like molecules using industry-centric drug discovery resources and...

Source

WARF Therapeutics spring 2021 call for proposals

Chris Najdowski — Mon, 01 Mar 2021 12:06:47 +0000

Program proposal deadline April 5 CONTACT: Jeanan Yasiri Moe Director of Strategic Communications jyasirimoe@warf.org | (608) 960-9892 MADISON, Wis. – WARF Therapeutics collaborates with researchers to advance their work closer to clinical testing, a “bench to bedside” approach. The program invests in the development of drug-like molecules using industry-centric drug discovery resources and...

Source

WARF Therapeutics 2020 call for fall proposals

warf_admin — Tue, 15 Sep 2020 15:16:43 +0000

CONTACT: Jacqui Fuller, Strategic Communications and Marketing Manager jfuller@warf.org | 608.960.9881 MADISON, Wis. – WARF Therapeutics encourages researchers working on a novel biological target to submit project proposals by October 15. The program works with researchers to advance work closer to clinical testing, a “bench to bedside” approach. It invests in the development of drug-like...

Source

WARF Therapeutics spring proposal deadline

warf_admin — Thu, 12 Mar 2020 17:00:03 +0000

Spring WARF Therapeutics (WT) Program Proposal Deadline: April 15 If you are a researcher working on a novel biological target, WARF Therapeutics may be able to help advance your work closer to clinical testing. WARF Therapeutics is run by preclinical drug discovery experts who have significant industry experience discovering drugs for novel targets. The program invests in the development of drug...

Source

Industry leaders join WARF Therapeutics Advisory Board

warf_admin — Mon, 22 Jul 2019 17:58:38 +0000

CONTACT: Jeanan Yasiri Moe, Director of Strategic Communications jyasirimoe@warf.org | 608.960.9892 MADISON, Wis. – WARF Therapeutics, the major drug discovery program launched this year by the Wisconsin Alumni Research Foundation (WARF), has named four pharmaceutical development experts to its Advisory Board with more than 100 years of combined preclinical and translational drug discovery...

Source

Despite the financial risks, new drug discovery vehicles proliferate on campus

warf_admin — Wed, 19 Jun 2019 19:30:45 +0000

19.19 | Technology Transfer Tactics | Original Publication | Download the pdf There is nothing like a big hit in the pharmaceutical space to put a university’s long-range plans for new research and infrastructure on a solid footing. In fact, large pharmaceutical companies are increasingly leaving the early-stages of drug development to universities and other research institutions. However...

Source

WARF bets big on new squad of drug hunters

warf_admin — Wed, 27 Feb 2019 21:57:34 +0000

27.19 | UW-Madison News | David Tenenbaum | Original Publication As it nears its 100th birthday, WARF — the Wisconsin Alumni Research Foundation, the nation’s first university technology transfer office — is embarking on a bold program to modernize what it has done so well, and so profitably, in past decades: advance basic discoveries from campus to the clinic and the patient. WARF Therapeutics...

Source